Meliam

Meloxicam, the active ingredient in Meliam, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It is indicated for the management of osteoarthritis, rheumatoid arthritis, musculoskeletal pain and acute pain in adult patients. GNH USA supplies Meliam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that acts on inflammatory pathways associated with joint and musculoskeletal disorders. - Osteoarthritis: reduces joint pain and inflammation, improving function and mobility. - Rheumatoid arthritis: alleviates chronic synovial inflammation and associated discomfort. - Musculoskeletal pain: provides relief from pain and swelling caused by strains, sprains or overuse. - Acute pain: offers short‑term analgesia for sudden inflammatory pain episodes.

Common Side Effects: - Gastro‑intestinal discomfort (nausea, dyspepsia) - Headache - Dizziness - Peripheral edema - Elevated blood pressure Serious or Rare Side Effects: - Gastro‑intestinal ulceration or bleeding - Cardiovascular events such as myocardial infarction or stroke - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis) - Renal impairment or failure - Hepatic enzyme elevation

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events. - Renal function: assess baseline creatinine and adjust use in renal impairment. - Blood pressure: monitor regularly, especially in hypertensive patients. - Gastro‑intestinal risk: avoid in patients with a history of ulcer disease unless gastro‑protective measures are in place. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Concomitant anticoagulants: use with caution due to increased bleeding risk. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Meloxicam may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): heightened bleeding potential. Moderate Interactions (Monitor Closely): - Diuretics: may reduce renal clearance of meloxicam. - Lithium: NSAIDs can raise lithium serum levels. - Methotrexate: reduced renal elimination may increase toxicity. - Cyclosporine: increased risk of nephrotoxicity. - ACE inhibitors or ARBs: may impair renal function, especially in volume‑depleted patients.